← AI Companies
Novo Nordisk is a Danish pharmaceutical company focused on diabetes and obesity treatments with no direct involvement in the AI ecosystem.
Snapshot
| Country |
DNK
|
| Exchange | Nasdaq CPH |
| AI Layer |
infra
|
| Sentiment |
68.0% |
| USD Mkt Cap | 189.49B |
| USD Revenue | 51.10B |
| USD Net Income | 18.06B |
| P/E | 10.53 |
| fwd P/E | 12.66 |
| PEG | 3.14 |
| Price 3M | -2.3% |
| Price 6M | +17.5% |
| Price 1Y | -16.6% |
| Price 2Y | -67.3% |
| USD Share Price | 43.53 |
Price & Size
| Price |
276.45 DKK |
| Market Cap |
1.22T DKK |
| Shares Outstanding |
3.34B |
| Shares Float |
3.17B |
| 52w Low |
224.25 DKK |
| 52w High |
409.95 DKK |
| Avg Volume |
4.25M |
Valuation
| P/E (trailing) |
10.5x |
| P/E (forward) |
12.7x |
| P/B |
5.53x |
| Enterprise Value |
1.32T DKK |
| Book Value / Share |
49.97 DKK |
| PEG Ratio |
3.14x |
| P/S |
3.71x |
| EV / Revenue |
4.00x |
| EV / EBITDA |
7.60x |
Income
| Revenue |
329.43B DKK |
| Revenue / Share |
74.19 DKK |
| EBITDA |
173.68B DKK |
| Net Income |
116.44B DKK |
| EPS (trailing) |
26.26 DKK |
| EPS (forward) |
21.84 DKK |
Margins & Profitability
| Gross Margin |
82.0% |
| Operating Margin |
42.5% |
| Profit Margin |
35.4% |
| EBITDA Margin |
52.7% |
| Return on Equity |
59.8% |
| Return on Assets |
18.7% |
Growth
| Revenue Growth |
2.1% |
| Earnings Growth |
-20.6% |
Cash & Debt
| Total Cash |
44.98B DKK |
| Total Debt |
140.13B DKK |
| Free Cash Flow |
37.67B DKK |
| Operating Cash Flow |
131.88B DKK |
| Debt / Equity |
0.63x |
| Current Ratio |
0.87x |
| Quick Ratio |
0.64x |
Dividend
| Rate |
11.70 DKK |
| Yield |
4.2% |
| Payout Ratio |
44.6% |
| Ex-Date |
2026-08-14 |
Analyst Consensus
| Target (Mean) |
310.17 DKK |
| Target (Median) |
300.00 DKK |
| Target (High) |
457.00 DKK |
| Target (Low) |
203.00 DKK |
| Recommendation |
hold |
| # Analysts |
23 |
Identifiers
| ISIN | DK0062498333 |
| SEDOL | 7133608 |
Sentiment 68.0%
as of Sep 12, 2026
Positive drivers
Novo Nordisk continued to report strong sales growth in its GLP-1 portfolio amid sustained global demand for obesity and diabetes treatments through mid-2026. The company's investments in AI-driven drug discovery and personalized medicine platforms yielded promising pipeline updates, enhancing long-term investor confidence. Positive analyst revisions and institutional buying supported the stock price during the period.
Neutral / mixed
Market volatility in the broader healthcare sector and fluctuating currency impacts from the Danish krone created mixed trading signals. Ongoing clinical trial readouts provided incremental data without major breakthroughs or setbacks. Investor focus remained balanced between near-term earnings and potential regulatory developments in key markets.
Negative drivers
Increased competition from emerging weight-loss therapies by rivals pressured market share expectations in some regions. Supply chain constraints and pricing negotiations with payers introduced short-term uncertainty. Macroeconomic concerns over healthcare spending cuts in Europe weighed on sentiment toward the end of the window.
Bottom line
Overall sentiment for Novo Nordisk remained moderately positive, anchored by its dominant position in high-growth therapeutic areas and AI-enhanced R&D efforts. While competitive and regulatory headwinds exist, the company's fundamentals continue to underpin a favorable outlook.